Compare ClearPoint Neuro Inc (CLPT) vs Vale SA (VALE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ClearPoint Neuro Inc vs Vale SA — how do they compare? ClearPoint Neuro Inc trades at $15.7 (market cap $478.63M), while Vale SA trades at $14.61 (market cap $60.78B). The key difference: Vale SA is far larger — about 127× ClearPoint Neuro Inc's market cap, and Vale SA pays a 8.63% dividend while ClearPoint Neuro Inc pays none. Which is the better fit depends on your goals.
| CLPT | VALE | |
|---|---|---|
Market Cap | $478.63M | $60.78B |
Sector | Health | Basic Materials |
52-Week High | $29.60 | $17.82 |
52-Week Low | $8.66 | $9.53 |
Enterprise Value | $506.63M | $77.70B |
Dividend Yield | — | 8.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ClearPoint Neuro (CLPT) trades at $16.51, down 5.66% on the day, with a bullish technical signal from moving averages but negative profitability. The company reported record Q1 2026 revenue of $36.97M with 25% organic device growth, though it missed EPS estimates with a $0.32 loss. Recent FDA clearance for the Velocity Alpha surgical drill and a partnership with Sungkyunkwan University highlight expansion efforts in neurosurgical navigation and drug delivery.
Outlook remains speculative with 100% analyst buy ratings anticipating gene therapy commercialization upside, but high execution and regulatory risks persist amid consistent losses and negative margins. The stock's valuation at 11.31x sales reflects growth expectations, yet cash burn from operations requires careful monitoring of financing sustainability.
VALE trades at $14.18, down 1.94% for the day, amid a bearish technical signal and mixed earnings history. The company reported revenue of $38.40B in 2025 with a net income margin of 7.21%, while recent news highlights a $2.6B decarbonization investment and governance developments. Cash flow remains positive, with operating cash flow at $8.80B in 2025.
The outlook is cautious; while analyst consensus is a Buy with a $17.50 price target, fundamental pressures from declining profit margins and a high debt-to-asset ratio of 24.66% pose risks. Upside depends on commodity price stability and execution of strategic investments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ClearPoint Neuro Inc
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →About Vale SA
Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.
Read more on VALE →
